Prostate Cell News Volume 9.07 | Feb 23 2018

TOP STORY

Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells

Investigators identified and quantified 16,130 transcripts and 7,209 proteins in castration resistant prostate cancer cell line, DU145. A total of 2,763 transcripts and 308 proteins were significantly altered upon knockdown of E6AP. Pathway analyses supported the known phenotypic effects of E6AP knockdown in prostate cancer cells and in parallel exposed novel potential links of E6AP with cancer metabolism, DNA damage repair and immune response. [Mol Cell Proteomics] Abstract | Full Article

(Ranked by impact factor of the journal)

Disruption of ETV6 Leads to TWIST1-Dependent Progression and Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Prostate Cancer

ETS variant gene 6 (ETV6) inhibited TWIST1 expression and disruption of ETV6 promoted TWIST1-dependent malignant phenotypes. Importantly, ETV6 was required to the anti-proliferation effects of epidermal growth factor receptor-tyrosine kinase inhibitors, partly due to the inhibitory function of ETV6 on TWIST1. [Mol Cancer] Full Article

An Indispensable Role of Androgen Receptor in Wnt Responsive Cells during Prostate Development, Maturation, and Regeneration

Deletion of Ar in embryonic Axin2-expressing cells impaired early prostate development in both ex vivo and tissue implantation experiments. When Ar expression was deleted in prostatic Axin2-expressing cells at pre-puberty stages, it resulted in smaller and underdeveloped prostates. [Stem Cells] Abstract

Protein Kinase D1 Regulates Subcellular Localisation and Metastatic Function of Metastasis-Associated Protein 1

Protein kinase D1 (PKD1)-mediated downregulation of metastasis-associated protein 1 (MTA1) was accompanied by a significant suppression of prostate cancer progression and metastasis in physiologically relevant spontaneous tumor models. Accordingly, progression of human prostate tumors to increased invasiveness was also accompanied by decreased and increased levels of PKD1 and MTA1, respectively. [Br J Cancer] Abstract

Identification of a Novel MicroRNA-mRNA Regulatory Biomodule in Human Prostate Cancer

To identify the crucial miRNA-mRNA regulatory biomodule involved into prostate carcinogenesis based on the previous miRNA expression profile in prostate cancer, investigators proposed an integrated systematic approach which combined miRNA-mediated gene expression regulatory network analysis, experimental validations in vitro and in vivo, as well as clinical significance evaluation. [Cell Death Dis] Full Article

Olaparib Is Effective in Combination With, and as Maintenance Therapy after, First-Line Endocrine Therapy in Prostate Cancer Cells

Scientists demonstrated that the LNCaP cell line, possessing multiple aberrations in BRCAness genes, is sensitive to Olaparib. [Mol Oncol] Abstract | Full Article

The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-Driven Prostate Cancer

The authors demonstrated that 4E-BP1 and 4E-BP2 act as essential metabolic breaks even in the context of aberrant mTOR activation and that they are essential for the creation of hypoxia tolerant cells in prostate cancer. [Mol Cancer Res] Abstract

UHRF1 Regulates CDH1 via Promoter Associated Non-Coding RNAs in Prostate Cancer Cells

Scientists showed that an antisense-directed ncRNA (paRCDH1-AS) transcribed from the CDH1 promoter is necessary for its expression. paRCDH1-AS acted as a hooking scaffold by recruiting the epigenetic regulators, UHRF1, DNMT3A, SUV39H1 and SUZ12, involved in CDH1 repression. [Biochim Biophys Acta] Abstract

p66shc Regulates Migration of Castration-Resistant Prostate Cancer Cells

Researchers hypothesized that p66Shc increases the migratory activity of prostate cancer (PCa) cells through reactive oxygen species and investigated the associated mechanism. Using the transwell assay, their study revealed that the level of p66Shc protein correlates with cell migratory ability across several PCa cell lines. [Cell Signal] Abstract

Efficacy of the Highly Selective Focal Adhesion Kinase Inhibitor Bi 853520 in Adenocarcinoma Xenograft Models Is Linked to a Mesenchymal Tumor Phenotype

The authors describe BI 853520, a novel ATP-competitive inhibitor distinguished by high potency and selectivity. In vitro, the compound inhibited focal adhesion kinase autophosphorylation in PC-3 prostate carcinoma cells with an IC₅₀ of 1 nmol/L and blocked anchorage-independent proliferation of PC-3 cells with an EC₅₀ of 3 nmol/L, whereas cells grown in conventional surface culture were 1000-fold less sensitive. [Oncogenesis] Full Article

Cellular Plasticity and the Neuroendocrine Phenotype in Prostate Cancer

Around one-quarter of resistant prostate tumors comprise cells that have undergone cellular reprogramming to become androgen receptor-independent and to acquire a continuum of neuroendocrine characteristics. These highly aggressive and lethal tumors, termed neuroendocrine prostate cancer, exhibit reactivation of developmental programs that are associated with epithelial–mesenchymal plasticity and acquisition of stem-like cell properties. [Nat Rev Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer

Poseida Therapeutics Inc. presented preclinical data on P-PSMA-101. P-PSMA-101 is the company’s PSMA-specific stem cell memory CAR-T drug candidate for the treatment of prostate cancer, which is the most common cancer among men in the United States. [Press release from Poseida Therapeutics Inc. discussing research presented at the 2018 Keystone Symposia on Emerging Cellular Therapies, Keystone] Press Release

Micromedic Reports Successful Clinical Study Results for the Detection of Prostate Cancer with a Non-Invasive Test

Micromedic Technologies announced successful results of a clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect^® technology. The study successfully detected cells originated from the prostate in urine samples. [Micromedic Technologies (PR Newswire Association LLC.)] Press Release

NeoTract Announces FDA Clearance of Expanded Indications for UroLift^® System

NeoTract announced that the FDA has cleared new indications for the UroLift^® System for the treatment of enlarged prostate, or benign prostatic hyperplasia. [NeoTract (BusinessWire Inc.)] Press Release

Half of Canada’s Government Scientists Still Feel Muzzled

More than half of government scientists in Canada—53%—do not feel they can speak freely to the media about their work, even after Prime Minister Justin Trudeau’s government eased restrictions on what they can say publicly, according to a survey released by a union that represents more than 16,000 federal scientists. [ScienceInsider] Editorial

Indonesian Scientists Hamstrung by Year-Long Funding Delay

Indonesian scientists expecting to receive hundreds of thousands of dollars for research are stuck in limbo because the country’s first dedicated science-funding agency is struggling to raise enough money. [Nature News] Editorial

Italian Election Leaves Science Out in the Cold

As campaigning ahead of Italy’s national election enters its final weeks, researchers in the country fear that budget cuts and declining interest in science will only continue — whatever the outcome of the vote. [Nature News] Editorial

NEW 8^th EACR-OECI Joint Course: Molecular Pathology Approach to Cancer
June 4-6, 2018
Amsterdam, Netherlands

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Associate – Prostate Research (Baylor College of Medicine)

Research Fellowship – Prostate Cancer Pathology (Weill Cornell Medicine)

Postdoctoral Scientist Opportunities – Biomedical Research (Cedars-Sinai)

Postdoctoral Fellow – Prostate Disease Research (Henry M. Jackson Foundation for the Advancement of Military Medicine)

Postdoctoral Scientist – Cancer Research (Boehringer Ingelheim)

Postdoctoral Fellow – Cancer Biology (Johns Hopkins University)

Scientist – Cancer Biology (Dana-Farber Cancer Institute)

Postdoctoral Research Fellow – Nuclear and Mitochondrial Mutagenesis in Carcinogenesis (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Cancer Biology (University of Pennsylvania)

Postdoctoral Fellow – Cancer Biology (Wake Forest Baptist Comprehensive Cancer Center)

Assistant Professor, Associate Professor & Professor – Cell & Molecular Biology (University of Mississippi)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.